thiazoles has been researched along with vosaroxin in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (10.53) | 29.6817 |
| 2010's | 32 (84.21) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, K; Kashimoto, S; Sato, Y; Shibamori, K; Tomita, K; Tsuzuki, Y | 1 |
| Fekrazad, HM; Mills, DA; Verschraegen, CF | 1 |
| Furutani, Y; Hoch, U; Kajikawa, F; Kashimoto, S; Lynch, J; Sato, Y; Silverman, JA | 1 |
| Allen, D; Evanchik, MJ; Hoch, U; Silverman, JA; Yoburn, JC | 1 |
| Arbitrario, JP; Fox, JA; Hawtin, RE; Howlett, AR; Kumer, JL; Scatena, CD; Silverman, JA | 1 |
| Adelman, DC; Advani, RH; Allen, RS; Berman, CJ; Ebbinghaus, SW; Fox, JA; Gordon, MS; Havrilla, NA; Hoch, U; Hurwitz, HI; Mendelson, DS; Silverman, JA; Wakelee, HA | 1 |
| Arkin, MR; Byl, JA; Conroy, A; Fox, JA; Hawtin, RE; McDowell, RS; Nguyen, T; Osheroff, N; Stockett, DE; Yang, W | 1 |
| Burnett, AK; Coles, SJ; Knapper, S; Walsby, EJ | 1 |
| Adelman, DC; Crawford, J; Ettinger, DS; Hoch, U; Krug, LM; Michelson, GC; Reiman, T; Shapiro, GI; Spigel, D; Temel, JS; Young, DY | 1 |
| Fox, JA; Hawtin, RE; Helleday, T; Lundin, C; Stockett, DE; Wong, OK | 1 |
| Allen, RS; Chen, T; Cripe, LD; Fox, JA; Giles, FJ; Kantarjian, HM; Karp, JE; Lancet, JE; List, AF; Michelson, GC; Ravandi, F; Ricklis, RM | 1 |
| Feldman, EJ | 1 |
| Camphausen, K; Gordon, IK; Graves, C; Kil, WJ; Kramp, T; Tofilon, P | 1 |
| Abbas, JA; Stuart, RK | 1 |
| Freeman, C; Giles, F; Keane, N; Swords, R | 1 |
| Lancet, JE | 1 |
| Chen, T; Craig, AR; Cripe, LD; Fox, JA; Hawtin, R; Karp, JE; Lancet, JE; Leavitt, RD; Maris, MB; Michelson, GC; Ravandi, F; Roboz, GJ; Stuart, RK | 1 |
| Borthakur, G; Cooper, MA; Costa, LJ; Cripe, LD; Dakhil, SR; Fox, JA; Leavitt, RD; Maris, MB; Mason, J; Michelson, GC; Ravandi, F; Shami, PJ; Stock, W; Stone, RM; Strickland, SA; Stuart, RK; Turturro, F | 1 |
| Cawthray, JF; Fox, JA; Jamieson, G; Mjos, KD; Orvig, C | 1 |
| Burnett, AK; Clark, RE; Dennis, M; Dignum, H; Hemmaway, C; Hills, RK; Kjeldsen, L; McMullin, MF; Milligan, D; Panoskaltsis, N; Russell, N; Thomas, IF | 1 |
| Hotinski, AK; Lewis, ID; Ross, DM | 1 |
| Acton, G; Carella, AM; Cortes, J; Craig, AR; Craig, MD; Damon, L; Derigs, HG; Erba, HP; Fox, JA; Gaidano, G; Havelange, V; Heuser, M; Hogge, D; Horst, HA; Jabbour, E; Kantarjian, HM; Klimek, VM; Lancet, JE; Maertens, J; Mehta, C; Odenike, O; Pigneux, A; Powell, BL; Ravandi, F; Recher, C; Ritchie, EK; Roboz, GJ; Sayar, H; Schiller, GJ; Smith, JA; Strickland, SA; Stuart, RK; Thomas, X; Vey, N; Ward, R; Wei, A | 1 |
| Ravandi, F; Short, NJ | 1 |
| Beijnen, JH; Fox, JA; Jamieson, G; Lucas, L; Nijenhuis, CM; Rosing, H; Schellens, JH | 1 |
| Fox, JA; Jamieson, GC; Poi, M; Strickland, SA | 1 |
| Benton, CB; Ravandi, F | 1 |
| Beijnen, JH; Fox, JA; Huitema, ADR; Jamieson, GC; Lucas, L; Mergui-Roelvink, M; Mould, DR; Nijenhuis, CM; Rosing, H; Schellens, JHM | 1 |
| Colapietro, A; Di Cesare, E; Festuccia, C; Fox, JA; Gravina, GL; Mancini, A; Marampon, F; Mattei, C; Rossi, G; Ventura, L; Vetuschi, A; Vitale, F | 1 |
| Paubelle, E; Thomas, X; Zylbersztejn, F | 1 |
| Acton, G; Carella, AM; Cortes, JE; Craig, AR; Craig, MD; Egyed, M; Fox, JA; Horst, HA; Jabbour, E; Kantarjian, HM; Klimek, VM; Krug, U; Lancet, JE; Pigneux, A; Ravandi, F; Récher, C; Ritchie, EK; Sayar, H; Schiller, GJ; Smith, JA; Strickland, SA; Stuart, RK; Vey, N; Ward, R | 1 |
| Yu, CZ; Zhao, XL | 1 |
| Che, F; Gui, C; Huang, J; Wang, C; Zhang, L | 1 |
| Gajda, M; Jasek-Gajda, E; Jasińska, M; Lis, GJ; Litwin, JA | 1 |
| Edwards, H; Ge, Y; Knight, T; Lin, H; Liu, F; Su, Y; Sun, L; Taub, JW; Wang, G; Wang, Y | 1 |
| Austin, CA; Bandak, A; Berger, JM; Blower, TR; Lee, ASY; Nitiss, JL | 1 |
| Jasek-Gajda, E; Jasińska, M; Jurkowska, H; Lis, GJ; Litwin, JA | 1 |
| Dasgupta, S; Kumar, A; Ojha, M; Yadav, D; Yadav, R | 1 |
| Kondapalli, VG; Mithula, S; Murugesan, S; Nandikolla, A | 1 |
11 review(s) available for thiazoles and vosaroxin
| Article | Year |
|---|---|
SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Humans; Naphthyridines; Neoplasms; Patents as Topic; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Thiazoles | 2008 |
Vosaroxin : a novel antineoplastic quinolone.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Randomized Controlled Trials as Topic; Thiazoles | 2012 |
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzothiazoles; Cytosine; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Naphthyridines; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Staurosporine; Survival Analysis; Thiazoles; Treatment Failure; Vorinostat | 2013 |
Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Recurrence; Thiazoles; Topoisomerase Inhibitors; Treatment Failure | 2015 |
The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Topics: Age Factors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Recurrence; Retreatment; Thiazoles; Treatment Outcome | 2016 |
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Haplorhini; Humans; Leukemia, Myeloid, Acute; Mice; Middle Aged; Naphthyridines; Quinolones; Rats; Thiazoles | 2016 |
Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Thiazoles; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; DNA Breaks, Double-Stranded; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Thiazoles; Topoisomerase Inhibitors | 2017 |
A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Bayes Theorem; Cytarabine; Disease-Free Survival; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Neoplasm Recurrence, Local; Odds Ratio; Pyrazoles; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles | 2018 |
1,8-Naphthyridine Derivatives: A Privileged Scaffold for Versatile Biological Activities.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Enoxacin; Fluoroquinolones; Gemifloxacin; Humans; Nalidixic Acid; Naphthyridines; Nitrogen; Polypharmacy; Thiazoles | 2021 |
1,8-naphthyridine derivatives: an updated review on recent advancements of their myriad biological activities.
Topics: Animals; Anti-Infective Agents; Antidepressive Agents; Antineoplastic Agents; Antioxidants; Antiviral Agents; Drug Discovery; Enoxacin; Humans; Isomerism; Molecular Structure; Nalidixic Acid; Naphthyridines; Neurodegenerative Diseases; Structure-Activity Relationship; Thiazoles | 2021 |
9 trial(s) available for thiazoles and vosaroxin
| Article | Year |
|---|---|
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Naphthyridines; Neoplasms; Quinolones; Recurrence; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
Topics: Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Naphthyridines; Neoplasm Staging; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Thiazoles; Treatment Outcome | 2011 |
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Neoplasm Staging; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Thiazoles; Treatment Outcome; Young Adult | 2011 |
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; Young Adult | 2015 |
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Prognosis; Survival Analysis; Thiazoles; Treatment Outcome | 2015 |
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Thiazoles | 2015 |
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Remission Induction; Thiazoles; Treatment Outcome | 2015 |
Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.
Topics: Adult; Aged; Biotransformation; Carbon Radioisotopes; Feces; Female; Humans; Injections, Intravenous; Male; Middle Aged; Naphthyridines; Neoplasms; Thiazoles; Topoisomerase II Inhibitors | 2017 |
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Recurrence; Thiazoles | 2018 |
18 other study(ies) available for thiazoles and vosaroxin
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mice; Naphthyridines; Neoplasm Transplantation; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Transplantation, Heterologous; Triazoles | 2004 |
Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthyridines; Neoplasms; Thiazoles; Xenograft Model Antitumor Assays | 2009 |
Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent.
Topics: Animals; Area Under Curve; Bile; Chromatography, High Pressure Liquid; DNA Damage; DNA Replication; Male; Naphthyridines; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Thiazoles | 2009 |
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow Cells; Cell Proliferation; Cytarabine; Disease Models, Animal; Drug Synergism; Female; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Leukocytes; Mice; Naphthyridines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thiazoles | 2010 |
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA; DNA Damage; DNA Fragmentation; DNA Topoisomerases, Type II; Drug Delivery Systems; Etoposide; G2 Phase; Humans; Intercalating Agents; Naphthyridines; Quinolones; Thiazoles | 2010 |
The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Topics: Apoptosis; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytarabine; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Deletion; Genes, p53; Humans; Lethal Dose 50; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cells; Naphthyridines; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; DNA Breaks, Double-Stranded; DNA Damage; DNA Fragmentation; DNA Repair; Doxorubicin; Drug Resistance, Neoplasm; Genes, BRCA2; Humans; Models, Biological; Naphthyridines; Recombination, Genetic; S Phase; Thiazoles | 2010 |
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles | 2011 |
Radiosensitization by the novel DNA intercalating agent vosaroxin.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Damage; DNA Repair; Flow Cytometry; Fluorescent Antibody Technique; Humans; Intercalating Agents; Naphthyridines; Radiation Tolerance; Radiation-Sensitizing Agents; Thiazoles | 2012 |
Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?
Topics: Anthracyclines; Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Thiazoles; Topoisomerase II Inhibitors | 2013 |
Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
Topics: Antineoplastic Agents; Doxorubicin; Drug Stability; Gallium; Iron; Models, Molecular; Molecular Conformation; Naphthyridines; Organometallic Compounds; Thiazoles | 2015 |
Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents; Body Fluids; Chemical Precipitation; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Methylation; Naphthyridines; Reproducibility of Results; Tandem Mass Spectrometry; Thiazoles | 2016 |
Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Survival; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Female; Glioblastoma; Humans; Leukocytes; Mice; Naphthyridines; Necrosis; Radiation Tolerance; Survival Rate; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Vosaroxin induces mitochondrial dysfunction and apoptosis in cervical cancer HeLa cells: Involvement of AMPK/Sirt3/HIF-1 pathway.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Aryl Hydrocarbon Receptor Nuclear Translocator; Female; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lipid Peroxidation; Mitochondria; Naphthyridines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirtuin 3; Superoxide Dismutase; Thiazoles; Uterine Cervical Neoplasms | 2018 |
TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; Cell Nucleus; Cell Survival; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; MAP Kinase Kinase Kinases; Microscopy, Confocal; Naphthyridines; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Reactive Oxygen Species; Thiazoles | 2018 |
Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Naphthyridines; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Thiazoles; Tumor Cells, Cultured; Young Adult | 2019 |
A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Ciprofloxacin; DNA; DNA Topoisomerases, Type II; Drug Resistance; High-Throughput Nucleotide Sequencing; Humans; Models, Molecular; Mutation; Naphthyridines; Nucleic Acid Conformation; Protein Binding; Protein Domains; Saccharomyces cerevisiae Proteins; Thiazoles; Topoisomerase II Inhibitors | 2019 |
Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Synergism; Humans; K562 Cells; Leukemia; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Naphthyridines; NF-kappa B; Signal Transduction; Thiazoles | 2019 |